Insulin maker Novo Nordisk will study the reduction of presence in Russia

The Danish insulin manufacturer Novo Nordisk may transfer the supply of drugs to Russia to another company. About it informed Kommersant, citing sources.

Swiss Swixx Biopharma may become a contender to manage Novo Nordisk’s business in the Russian Federation. According to one of the interlocutors, earlier the Russian businesses of other Western companies, in particular the American Eli Lilly and Bristol-Myers Squibb (BMS), were transferred to the Swiss company.

20 April RBC with reference to the letter of the Russian Association of Pharmacy Chains (RAAS) to Roszdravnadzor wrotethat Novo Nordisk’s Ozempic drug for patients with diabetes appeared in pharmacies in “questionable packaging” and at a price three to four times higher than the marginal cost. The termination of supplies of Ozempik was also reported at the end of March of this year, later in Roszdravnadzor assuredthat the supply of this medicine is ongoing and will continue until at least December 2023.

The RAAS paid attention to the rise in prices for the drug for a long time – six months ago. The marginal price for Ozempik, included in the list of vital and essential drugs, in Moscow and the region should not exceed 7800 rubles. At the same time, the newspaper found 64 offers on the AptekaMos.ru service in various dosages at a price of 15,000 rubles. for packing.

A week before, on April 13, TASS, citing Roszdravnadzor informedthat the Rebelsas drug from the same Danish company will no longer be supplied from 2024. At the same time, the department said that in the first three months of 2023, 9,240 packages of the drug were released into circulation, and supplies will continue until the end of the year.